Problem/Issue Statement
· They currently utilize a paper-based process which requires each site coordinator to transfer updates from patient’s medical records over to CRF binders after each patient visit. A CRA visits each site on a monthly basis to manually error check the CRF’s to ensure they matched patient records exactly. Once a CRF page was verified, it would be sent to the Clinical Operations Department for data entry when it would be entered manually into a data base not once but twice to check for errors in data entry. If there were discrepancies, it would need to be entered a third or forth time until the data was confirmed. If a “query” was identified, the CRA would be informed and would then work with the investigator site to resolve the error, further delaying the actual verification of data. Once all the CRF pages were verified, the data would become “unblinded” allowing for several departments begin their analysis of the data.
· As you can see, P&G’s clinical trial process is both very time consuming and labor intensive. They need to find ways to streamline the process without comprising the accuracy of data. As noted in the case study; each day the average prescription drug is delayed represents a loss of $1M dollars.
· Ray D’Alonzo has been tasked to identify ways P&G’s can shorten then length of time spent on clinical trial process while still allowing for accurate data and thorough analysis.
Situation Assessment
After doing his initial research, D’Alonzo determined that the solution to their problem would come with the implementation of EDC. It looked as if the use of EDC could likely cut the “data lock” period in half while still ensuring accurate data. While eager to learn more about the EDC process, he was also hesitant as he realized P&G would be one of the first large pharmaceutical companies to adopt this new process. He wondered why other larger companies had not yet jumped on board; he wondered if he was missing something.
List of Alternative Courses of Action
D’Alonzo identified three potential solutions to their problem:
· Improving the paper-based process: P&G could make small changes to the process such as using express mail and increased staffing to allow for faster data entry and source-data verification
· Digital Imaging: Data could be electronically transmitted from the investigator to P&G. CRFs could be faxed and digitally scanned for data retrieval. The double entry system would still exist but employees would enter the data using a split screen allowing the document image to be visible during data entry. All documents which were now stored as images would need to be archived and labeled properly. The rest of the process would remain unchanged.
· Web-enabled electronic data capture (EDC): CRF data would be entered into a web-based data collection tool directly by the investigator. The double-entry data method would be eliminated; potential queries could be addressed and corrected much sooner due to an automated validation process. This seemed like the only way to truly influence the current process.
Evaluation of Alternatives
· Improving the paper-based process: I see no true improvement with this approach. Both Express Mail and increased staffing will cost P&G more money and will only cut down on the total process by a few days.
· Digital Imaging: Although this approach does allow for a faster transmission of data from investigators to P&G, it does not affect the process in any other way. Documents which would be stored as images need proper labeling and archiving required more time. P&G would also need to significantly increase their storage memory in order to support all of the CRF images.
· Web-enabled electronic data capture (EDC): This appears to be the only way to actually improve the process and significantly reduce time spent in the data lock period. Data entry and validation becomes completely automated. Human error is no longer a factor in data entry ensuring the data remains accurate. Trial specific validation processes will be put in place allowing queries to be corrected much faster. Validated data also becomes available for analysis much faster and is more accessible to the multiple departments who utilize it. After researching several different EDC options and comparing Features/Benefits vs. cost of implementation for each option, D’Alonzo decided Phase Forward would best improve their process. Not only does Phase Forward offer EDC software, but they also provide services such as maintenance of e-CRF’s and a help desk.
Final Recommendation
For all of the reasons mentioned above, my recommendation will be to move forward with Phase Forward. Trials which have already begun using the paper-based system should be finished using the paper-based system. All future trials should utilize Phase Forward. A formal training system needs to be in place for the P&G employees as well as the investigator sites. Investigator sites also may need to be provided with computers, internet access and Live Help to ensure they are using the site correctly. There should be a change management team in place to identify all of the ways the process change will affect employees and their responsibilities. While these costs add up rather quickly, so does $1M for each day P&G delays a prescription drug launch. P&G paid anywhere from $250-450K per trial. Even if Phase Forward eliminated only one day from the trial period, it represents $1M worth of sales that P&G would have otherwise lost.